1. Scrip

Dr Reddy’s Faces US Class Action Case Heat

 
• By Anju Ghangurde

Pressure builds on Dr Reddy’s Laboratories after at least two US law firms press ahead with a class action case against the company. Analysts appear unperturbed, however – at least for now – about the possibility of any material implications.

Hammer
DR REDDY'S FACES LEGAL ACTION IN THE US

Dr. Reddy's Laboratories Ltd. is facing legal action in the US for allegedly failing to make adequate disclosures pertaining to its quality system, with at least two US law firms now pursuing a class action suit against it claiming that ensuing regulatory action dented the company’s share price, with investors suffering “damages” when the “true details” emerged.

Faruqi & Faruqi LLP has filed a lawsuit in the US District Court for the District of New Jersey against...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

KalVista’s Delayed FDA Approval In HAE Comes Through

 
• By Joseph Haas

KalVista’s Ekterly obtains US approval as the first oral, on-demand therapy for hereditary angioedema. It will compete with established injectables.

Cogent Peaks With Bezaclastinib SUMMIT Results

 
• By Alaric DeArment

The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By Kevin Grogan

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.